Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited is a global pharmaceutical manufacturer specializing in generic medicines, specialty drugs, and biopharmaceutical products across CNS, respiratory, oncology, and other therapeutic areas. Investors research TEVA because it operates in the resilient generic drug market while carrying significant debt and facing valuation questions relative to earnings growth.
Get a full AI research report on TEVA
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Teva Pharmaceutical Industries Limited do?
Teva generates revenue by developing, manufacturing, and distributing generic medicines in multiple dosage forms, sterile products, and branded specialty drugs including COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and AUSTEDO (tardive dyskinesia). The company also provides active pharmaceutical ingredients and contract manufacturing services to other pharmaceutical firms. Its business model relies on scale in generics—where margins are lower but volumes are high—combined with higher-margin specialty and branded products to offset pricing pressure.
Bull case
- ✓Gross margin of 52.5% demonstrates pricing power and operational efficiency in a competitive generic drug market.
- ✓Diversified product portfolio across CNS, respiratory, and oncology reduces dependence on any single therapeutic area or market.
- ✓Forward P/E of 46.3 is lower than trailing P/E of 67.1, suggesting market expectations for earnings growth acceleration.
- ✓PEG ratio of 1.06 indicates valuation may be reasonable relative to projected earnings growth rate.
- ✓Established branded specialty drugs (COPAXONE, AJOVY, AUSTEDO) provide recurring revenue streams with higher margins than generic products.
Bear case
- ✗Debt-to-equity ratio of 217.8% signals heavy leverage and financial risk, limiting flexibility for acquisitions or downturns.
- ✗Current ratio of 0.88 and quick ratio of 0.46 indicate potential liquidity constraints and difficulty meeting short-term obligations.
- ✗Trailing P/E of 67.1 remains elevated, and net margin of only 4.1% leaves little room for operational missteps.
- ✗Generic drug pricing pressure from regulatory scrutiny and competition could compress margins further.
- ✗Return on equity of 9.7% and return on assets of 5.1% are modest, raising questions about capital efficiency given the debt load.
TEVA valuation & financial health
Teva trades at a trailing P/E of 67.1 with a forward P/E of 46.3, suggesting the market prices in near-term earnings improvement. The PEG ratio of 1.06 implies valuation is not extreme relative to growth expectations, though the trailing multiple remains elevated. Gross margins of 52.5% are healthy, but operating margin of 4% and net margin of 4.1% are thin, reflecting competitive pressures in generics. The critical concern is the debt-to-equity ratio of 217.8% paired with a current ratio of 0.88, indicating the company carries substantial leverage relative to equity and may face liquidity stress. ROE of 9.7% and ROA of 5.1% are modest returns for a leveraged balance sheet, suggesting capital is not being deployed efficiently. The company pays no dividend and retains earnings, prioritizing debt reduction.
The bottom line
Teva presents a classic tension between a resilient, diversified pharmaceutical business and a highly leveraged balance sheet with thin operating margins. The forward valuation appears more reasonable than the trailing multiple, and the PEG ratio suggests growth expectations are not extreme; however, the combination of high debt, low liquidity ratios, and modest returns on capital warrants careful monitoring of debt reduction progress and operating margin trends. Key factors to weigh include whether specialty drug revenue can offset generic pricing pressure, whether the company can sustain earnings growth to justify the forward multiple, and whether management can meaningfully reduce leverage without sacrificing R&D or market position. Investors should track quarterly earnings, debt levels, and competitive dynamics in key therapeutic areas before forming a conviction.
Frequently asked questions
What does Teva Pharmaceutical Industries Limited do?
Teva develops, manufactures, and distributes generic medicines, specialty pharmaceuticals, and biopharmaceutical products globally. Its portfolio includes generic drugs across multiple dosage forms, branded specialty drugs for multiple sclerosis and migraine, and active pharmaceutical ingredients for other manufacturers.
Is TEVA a good stock to research?
TEVA is worth researching if you are interested in the generic pharmaceutical sector, but it requires careful analysis of its debt burden and operating margins. The company operates in a resilient market but faces leverage and liquidity concerns that differentiate it from lower-debt peers.
Is TEVA overvalued?
The trailing P/E of 67.1 appears elevated, but the forward P/E of 46.3 and PEG ratio of 1.06 suggest the market is pricing in earnings growth. Whether that growth materializes depends on specialty drug performance and generic margin stability, making valuation assessment dependent on operational execution.
What are Teva's main risks?
Key risks include high debt (debt-to-equity of 217.8%), weak liquidity (current ratio of 0.88), generic drug pricing pressure, and thin operating margins (4%). Any slowdown in specialty drug sales or further generic price erosion could strain the balance sheet.
Does Teva pay a dividend?
No, Teva does not currently pay a dividend. The company retains earnings and prioritizes debt reduction over shareholder distributions.
What is Teva's competitive position?
Teva is one of the world's largest generic pharmaceutical manufacturers with scale and diversified products, but it competes in a commoditized market where pricing is under constant pressure. Its specialty drug portfolio (COPAXONE, AJOVY, AUSTEDO) provides differentiation and higher margins.
Research TEVA with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.